S&P 500   4,563.85 (-0.07%)
DOW   36,138.40 (+0.04%)
QQQ   386.41 (-0.23%)
AAPL   192.88 (-0.28%)
MSFT   369.79 (-0.73%)
META   319.04 (+0.24%)
GOOGL   130.55 (-0.34%)
AMZN   145.78 (-0.75%)
TSLA   242.00 (+1.37%)
NVDA   458.64 (-1.51%)
NIO   7.84 (+5.52%)
BABA   72.07 (-0.43%)
AMD   116.91 (-1.24%)
T   17.01 (-1.22%)
F   10.76 (+1.51%)
MU   73.52 (-0.23%)
CGC   0.70 (+4.61%)
GE   120.53 (+0.25%)
DIS   91.62 (+0.91%)
AMC   6.91 (-1.57%)
PFE   28.94 (-0.52%)
PYPL   59.99 (+3.57%)
XOM   99.01 (-1.42%)
S&P 500   4,563.85 (-0.07%)
DOW   36,138.40 (+0.04%)
QQQ   386.41 (-0.23%)
AAPL   192.88 (-0.28%)
MSFT   369.79 (-0.73%)
META   319.04 (+0.24%)
GOOGL   130.55 (-0.34%)
AMZN   145.78 (-0.75%)
TSLA   242.00 (+1.37%)
NVDA   458.64 (-1.51%)
NIO   7.84 (+5.52%)
BABA   72.07 (-0.43%)
AMD   116.91 (-1.24%)
T   17.01 (-1.22%)
F   10.76 (+1.51%)
MU   73.52 (-0.23%)
CGC   0.70 (+4.61%)
GE   120.53 (+0.25%)
DIS   91.62 (+0.91%)
AMC   6.91 (-1.57%)
PFE   28.94 (-0.52%)
PYPL   59.99 (+3.57%)
XOM   99.01 (-1.42%)
S&P 500   4,563.85 (-0.07%)
DOW   36,138.40 (+0.04%)
QQQ   386.41 (-0.23%)
AAPL   192.88 (-0.28%)
MSFT   369.79 (-0.73%)
META   319.04 (+0.24%)
GOOGL   130.55 (-0.34%)
AMZN   145.78 (-0.75%)
TSLA   242.00 (+1.37%)
NVDA   458.64 (-1.51%)
NIO   7.84 (+5.52%)
BABA   72.07 (-0.43%)
AMD   116.91 (-1.24%)
T   17.01 (-1.22%)
F   10.76 (+1.51%)
MU   73.52 (-0.23%)
CGC   0.70 (+4.61%)
GE   120.53 (+0.25%)
DIS   91.62 (+0.91%)
AMC   6.91 (-1.57%)
PFE   28.94 (-0.52%)
PYPL   59.99 (+3.57%)
XOM   99.01 (-1.42%)
S&P 500   4,563.85 (-0.07%)
DOW   36,138.40 (+0.04%)
QQQ   386.41 (-0.23%)
AAPL   192.88 (-0.28%)
MSFT   369.79 (-0.73%)
META   319.04 (+0.24%)
GOOGL   130.55 (-0.34%)
AMZN   145.78 (-0.75%)
TSLA   242.00 (+1.37%)
NVDA   458.64 (-1.51%)
NIO   7.84 (+5.52%)
BABA   72.07 (-0.43%)
AMD   116.91 (-1.24%)
T   17.01 (-1.22%)
F   10.76 (+1.51%)
MU   73.52 (-0.23%)
CGC   0.70 (+4.61%)
GE   120.53 (+0.25%)
DIS   91.62 (+0.91%)
AMC   6.91 (-1.57%)
PFE   28.94 (-0.52%)
PYPL   59.99 (+3.57%)
XOM   99.01 (-1.42%)

Beam Therapeutics Stock Price, News & Analysis (NASDAQ:BEAM)

$29.40
+1.15 (+4.07%)
(As of 02:34 PM ET)
Compare
Today's Range
$28.27
$29.86
50-Day Range
$17.69
$30.76
52-Week Range
$16.95
$51.60
Volume
471,226 shs
Average Volume
986,953 shs
Market Capitalization
$2.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.80

Beam Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.45 Rating Score
Upside/​Downside
67.2% Upside
$48.80 Price Target
Short Interest
Bearish
16.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Beam Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$73,343 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.85) to ($4.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

474th out of 949 stocks

Biological Products, Except Diagnostic Industry

71st out of 146 stocks


BEAM stock logo

About Beam Therapeutics Stock (NASDAQ:BEAM)

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Stock Price History

BEAM Stock News Headlines

CRISPR Gene Editing: Beam Therapeutics
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Is Beam Therapeutics Stock a Buy Now?
What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Lilly buys out Beam in heart drug alliance with Verve
Beam sells opt-in rights to Eli Lilly for up to $600M
See More Headlines
Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BEAM
Fax
N/A
Employees
439
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$48.80
High Stock Price Target
$105.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+72.7%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

Net Income
$-289,090,000.00
Net Margins
-384.62%
Pretax Margin
-383.39%

Debt

Sales & Book Value

Annual Sales
$60.92 million
Book Value
$10.41 per share

Miscellaneous

Free Float
77,918,000
Market Cap
$2.30 billion
Optionable
Not Optionable
Beta
1.69

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report














BEAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price target for 2024?

11 brokerages have issued twelve-month target prices for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $105.00. On average, they expect the company's stock price to reach $48.80 in the next year. This suggests a possible upside of 67.2% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2023?

Beam Therapeutics' stock was trading at $39.11 at the start of the year. Since then, BEAM stock has decreased by 25.4% and is now trading at $29.19.
View the best growth stocks for 2023 here
.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our BEAM earnings forecast
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its earnings results on Wednesday, November, 8th. The company reported ($1.22) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The firm earned $17.20 million during the quarter, compared to analysts' expectations of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 40.66% and a negative net margin of 384.62%. Beam Therapeutics's quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.56) EPS.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.09%), FMR LLC (7.97%), Sumitomo Mitsui Trust Holdings Inc. (2.07%), Redmile Group LLC (1.80%), Baillie Gifford & Co. (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends
.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
This page (NASDAQ:BEAM) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -